Skip to content
Research Article Open access CC BY 4.0

Synthesis and Characterization of Impurities of a Common and Advanced Intermediate of Candesartan and Azilsartan Antihypertensive Drugs

Sangeeta Sangwan, Tapas Panda, Kaushal Nayyar, Sharwan K. Dewan, Rajesh K. Thaper

International Research Journal of Pure and Applied Chemistry · pp. 140–149 · Published 6 Nov 2014

10.9734/IRJPAC/2015/13162

Abstract

Six impurities were identified in the lab development batches during the course of benzimidazole intermediate (1) synthesis by reverse phase HPLC method. Intermediate 1 is used as a common and advanced intermediate in the synthesis of candesartan and azilsartan. All the impurities were characterized by IR, NMR, LC/MS and CHN analyses, which included an isomer of intermediate 11 (impurity 19), desethyl analogue of 1 (impurity 20), desethoxy analogue of 1 (impurity 21), methyl analogue of 1 (impurity 22), cyanobiphenyl benzimidazole (impurity 25) and cyanobiphenyl derivative of 1 (impurity 26). The synthesis and characterization of these impurities are presented.

Candesartan azilsartan benzimidazole impurity API and intermediate

References (13)

  1. 1 Angiotensin Receptors and Their Antagonists [DOI]
  2. 2 Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids [DOI]
  3. 3 Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids [DOI]
  4. 4 Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles [DOI]
  5. 5 One-Pot Synthesis of 1H-Benzimidazole Derivatives Using Thiamine Hydrochloride as a Reusable Organocatalyst [DOI]
  6. 6 LC and LC–MS/TOF studies on stress degradation behaviour of candesartan cilexetil [DOI]
  7. 7 Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure [DOI]
  8. 8 Improved Process for Azilsartan Medoxomil: A New Angiotensin Receptor Blocker [DOI]
  9. 9 A novel and practical synthesis of substituted 2-ethoxy benzimidazole: candesartan cilexetil [DOI]
  10. 10 Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). [DOI]
  11. 11 Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR [DOI]
  12. 12 Synthesis of Azilsartan and Its Selected Potential Impurities [DOI]
  13. 13 Identification, synthesis and structural determination of some impurities of candesartan cilexetil [DOI]

Cited by 6

Synthesis and characterization of related substances of Azilsartan Kamedoxomil

N. V. D. Harikiran Maddi, Srinivas Garaga, Ambati V. Raghava Reddy · Current Issues in Pharmacy and Medical Sciences · 2017

Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116

Ana Testen, Miha Plevnik, Bogdan Štefane · Acta Pharmaceutica · 2018

Showing 3 of 6 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

34

Page views

0

PDF downloads

9

Outbound clicks

6

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.